Cargando…
Gene therapy in neuromuscular disorders
Monogenic neuromuscular disorders are potentially treatable through gene therapy. Using viral vectors, a therapeutic transgene aims to restore normal levels of a protein not produced by the defective gene, or to silence a gene whose expression leads to toxic effects. Spinal Muscular Atrophy (SMA) is...
Autores principales: | Mendonça, Rodrigo Holanda, Zanoteli, Edmar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academia Brasileira de Neurologia - ABNEURO
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491441/ https://www.ncbi.nlm.nih.gov/pubmed/35976325 http://dx.doi.org/10.1590/0004-282X-ANP-2022-S135 |
Ejemplares similares
-
Inflammatory myopathies: an update for neurologists
por: Silva, André Macedo Serafim, et al.
Publicado: (2022) -
Myasthenia gravis in clinical practice
por: Estephan, Eduardo de Paula, et al.
Publicado: (2022) -
Diagnostic NGS for Severe Neuromuscular Disorders
por: Dhamija, Radhika, et al.
Publicado: (2015) -
The influence of tone on proximal femoral and acetabular geometry in
neuromuscular hip displacement: A comparison of cerebral palsy and spinal
muscular atrophy
por: Ulusaloglu, Armagan Can, et al.
Publicado: (2022) -
European Neuromuscular Centre consensus statement on anaesthesia in patients with neuromuscular disorders
por: van den Bersselaar, Luuk R., et al.
Publicado: (2022)